Compare First Citizens BancShares Inc (FCNCA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Sanofi SA — how do they compare? First Citizens BancShares Inc trades at $2,066.27 (market cap $22.94B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 4.1× First Citizens BancShares Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Sanofi SA for 94 Days on average.
| FCNCA | SNY | |
|---|---|---|
Market Cap | $22.94B | $95.18B |
Volume | 91,668 | 2,995,646 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $52.34 |
52-Week Low | $1.64K | $39.51 |
Typical Hold Time | 29 Days | 94 Days |
Dividend Yield | 0.41% | 6.01% |
Enterprise Value | — | $114.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,071.56, down 0.79% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with a P/E of 11.11 and net income margin of 25.23%, and has beaten EPS estimates for the last three quarters. Recent corporate actions include a $2.10 dividend and expansion through branch acquisitions and new financing initiatives.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but near-term technical weakness and high institutional hold ratings suggest caution. Key risks include execution of growth initiatives and broader economic pressures on banking.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
